Robert W. Baird analyst Jack Allen maintained a Buy rating on MiNK Therapeutics (INKT – Research Report) yesterday and set a price target of $8.00. The company’s shares opened today at $1.78.
Allen covers the Healthcare sector, focusing on stocks such as Lineage Therap, Vor Biopharma, and Bluebird Bio. According to TipRanks, Allen has an average return of -17.8% and a 35.90% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for MiNK Therapeutics with a $8.33 average price target, a 367.98% upside from current levels. In a report released today, B.Riley Financial also reiterated a Buy rating on the stock with a $7.00 price target.
See the top stocks recommended by analysts >>
INKT market cap is currently $66.09M and has a P/E ratio of -2.51.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INKT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other life-threatening illnesses.
Read More on INKT:
